Vanda Pharmaceuticals Inc

NASDAQ: VNDA
$5.19
+$0.17 (+3.4%)
Closing Price on November 8, 2024

VNDA Stock Chart and Intraday Price

VNDA Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 265.25M USD
Shares Outstanding 57,538,000
Vanda Pharmaceuticals Inc is a biopharmaceutical company dedicated to creating treatments for a variety of health conditions with unmet medical needs around the globe. It markets HETLIOZ for non-24-hour sleep-wake disorders and Fanapt for schizophrenia. The company is also developing treatments for conditions like jet lag, insomnia, bipolar I disorder, and Parkinson’s disease psychosis, among others. Additionally, Vanda is working on therapies for gastroparesis, motion sickness, and certain dermatological and respiratory conditions. Founded in 2002, Vanda is based in Washington, D.C.

VNDA Articles

Friday Afternoon's Top Analyst Upgrades and Downgrades: BP, Carvana, Iron Mountain, Latch, LivePerson and More
Friday afternoon's top analyst upgrades and downgrades included BP, Carvana, Iron Mountain, Latch and LivePerson.
Chris Lange
Published:

Amazon, Caterpillar, Disney, EA, Target and More Wednesday Afternoon Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Amazon, Caterpillar, Disney, EA, Target and more.
Chris Lange
Published:

Vanda Investors Can Sleep Easy With This FDA Approval
Vanda Pharma shares jumped on Wednesday after the company announced an update from the FDA regarding its treatment for nighttime sleep disturbances associated with Smith-Magenis syndrome.
Chris Lange
Published:

Vanda Pharma's Big Step Forward in COVID-19 Pneumonia
Vanda Pharmaceuticals took another big step forward in the fight against COVID-19 on Tuesday morning.
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: Avaya, Biogen, Broadcom, Chevron, Domino's, eBay, MGIC, RealReal, Sprout Social, T-Mobile, Zoom, Zynga and More
Tuesday's top analyst upgrades and downgrades included Avaya, Biogen, Broadcom, Chevron, Domino's Pizza, eBay, MGIC Investment, RealReal, Sprout Social, T-Mobile, Zoom Video Communications and Zynga.
Jon C. Ogg
Published:
Last Updated:

Why the FDA Is a Little Slow on This Jet Lag Study
Vanda Pharma shares dropped early to start out the week after the frim announced that it received a Complete Response Letter from the FDA.
Chris Lange
Published:
Last Updated:

Top Analyst Upgrades and Downgrades: Allstate, Corning, DexCom, Lam Research, On Deck, Qualcomm, Spotify, Western Digital, Whiting Petroleum and More
The top analyst upgrades, downgrades and initiations seen on Thursday included Allstate, Corning, DexCom, Lam Research, On Deck, Qualcomm, Spotify, Western Digital and Whiting Petroleum.
Jon C. Ogg
Published:
Last Updated:

Top Analyst Upgrades and Downgrades: AT&T, Caterpillar, Dollar General, EA, Etsy, Facebook, Spirit Airlines, Tesla, Xilinx and More
The top analyst upgrades, downgrades and initiations seen on Thursday included AT&T, Caterpillar, Dollar General, Electronic Arts, Etsy, Facebook, Spirit Airlines, Tesla and Xilinx.
Jon C. Ogg
Published:
Last Updated:

Top Analyst Upgrades and Downgrades: DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap, Vishay and More
The top analyst upgrades, downgrades and initiations seen on Wednesday included DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap and Vishay.
Jon C. Ogg
Published:
Last Updated:

Top Analyst Upgrades and Downgrades: Abbott Labs, Apple, Apptio, Cheniere, First Solar, Kratos, Smartsheet, UPS, Waste Management and More
The top analyst upgrades, downgrades and initiations seen on Tuesday included Abbott Laboratories, Apple, Apptio, Cheniere Energy, First Solar, Kratos Defense & Security Solutions, Smartsheet,...
Jon C. Ogg
Published:
Last Updated:

Vanda Pharma Nails Midstage Gastroparesis Study
Vanda Pharmaceuticals shares made a solid gain on Monday after the firm announced results from a midstage trial of patients with idiopathic and diabetic gastroparesis.
Chris Lange
Published:
Last Updated:

Top Analyst Upgrades and Downgrades: AMD, Chevron, GM, Intel, Merck, Nokia, Under Armour and More
The top analyst upgrades, downgrades and other research calls from Monday include AMD, Chevron, GM, Intel, Merck, Nokia and Under Armour.
Jon C. Ogg
Published:
Last Updated:

Top Analyst Upgrades and Downgrades: Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess, Western Digital and More
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess and Western Digital.
Jon C. Ogg
Published:
Last Updated:

Jefferies Has 5 Top Biotech Stocks to Buy for 2017
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
Lee Jackson
Published:
Last Updated:

Top Biotech Plays Highlight Jefferies Growth Stocks to Buy
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.
Lee Jackson
Published:
Last Updated: